[{"orgOrder":0,"company":"Sairopa","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"$335.0 million","upfrontCash":"$40.0 million","newsHeadline":"Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRP\u03b1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sairopa","sponsor":"Exelixis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"}]
Find Clinical Drug Pipeline Developments & Deals by Sairopa
ADU-1805 is a monoclonal antibody which blocks SIRPα, a significant immune-suppressive component of the tumor microenvironment which leads in improved immune system’s ability to attack tumors.
Exelixis and Sairopa will develop ADU-1805, a potentially best-in-class monoclonal antibody that targets SIRPα. ADU-1805 is active against all human alleles of SIRPα, which may allow it to address a broader patient population than other SIRPα-directed therapies.